Compare Nomura Holdings Inc (NMR) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nomura Holdings Inc vs Philip Morris International Inc. — how do they compare? Nomura Holdings Inc trades at $9.49 (market cap $28.05B), while Philip Morris International Inc. trades at $200.2 (market cap $300.33B). The key difference: Philip Morris International Inc. is far larger — about 10.7× Nomura Holdings Inc's market cap, and Nomura Holdings Inc pays the higher dividend (3.4%). Which is the better fit depends on your goals — on Pluang, investors hold Nomura Holdings Inc for 55 Days and Philip Morris International Inc. for 85 Days on average.
| NMR | PM | |
|---|---|---|
Market Cap | $28.05B | $300.33B |
Volume | 729,574 | 3,935,700 |
Sector | Financials | Consumer Staples |
52-Week High | $10.86 | $200.50 |
52-Week Low | $6.73 | $144.33 |
Typical Hold Time | 55 Days | 85 Days |
Enterprise Value | $38.55T | $343.44B |
Dividend Yield | 3.4% | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nomura Holdings (NMR) trades at $9.54, down 2.45% today, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with revenue growth from $1.38T in 2024 to $1.66T in 2025 and net income surging to $340.74B. Valuation metrics appear attractive with P/E of 11.29 and P/B of 1.15, while analyst consensus leans toward Hold (66.67%) with some positive momentum coverage from Zacks.
The outlook presents a mixed picture - strong profitability and reasonable valuation support upside potential, but negative operating cash flows and increasing debt-to-asset ratios pose significant risks. Recent technical weakness suggests near-term pressure, though fundamental strength could drive recovery if earnings momentum continues.
Philip Morris International (PM) trades at $200.5, up 5.3% over 24 hours, with a bullish technical signal and strong earnings beats in Q1 and Q2 2026. The company shows robust fundamentals with 2025 revenue of $40.65B and net income of $11.35B, supported by a 67.48% gross margin. Recent news highlights expansion of smoke-free products like ZYN and IQOS, now over 40% of revenue, driving growth amid industry shifts.
Outlook is positive with analyst consensus at Buy (68%) and a $212.17 price target, though elevated P/E of 26.46 and regulatory risks in tobacco remain concerns. Earnings growth and smoke-free product adoption are key catalysts, but investors should monitor debt levels and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
